Doctor reported outcomes: Real-world data from a tertiary eye cancer center

e16578 Background: Cabozantinib is a multitarget tyrosine kinase inhibitor and getting attention in these days through its combination with immune checkpoint inhibitors. In this article, we analyze the efficacy of cabozantinib in patients with metastatic ccRCC in Korean who had progression after 1 or more VEGFR TKI therapies. Methods: Seventy-five patients from Jan.2019 to Dec. 2021 at Yonsei Cancer Center who had received cabozantinib treatment in second to fourth line of therapy were retrospectively reviewed. The primary endpoint was PFS. The secondary outcomes were the response rate, disease control rate (DCR), and OS. The evaluable subjects for efficacy were those who had at least one response evaluation. Results: Among 75 patients, 57 (76.0%) were male and median age was 59 years (range 33-81). Median follow up time was 12.1 months. There were 22 (29.3%) patients of second line, 38 (50.7%) of third line and 15 (20.0%) of fourth line of treatment. Median PFS was 5.6 months (95% CI, 4.6-6.6). Median OS was 13.6 months (95% CI, 5.0-22.2). The PFS based on the line of treatment was 4.7 months for second line, 5.6 months for third line and 12.0 months for 4th line. Proportion of patients who were previously treated with ICI was different between treatment line groups and showed increasing trend toward later line; 13.6% of second line, 31.6% of third line, and 66.7% of fourth line, respectively. The objective response rate was 8.0% with 6 patients of partial response. The DCR was 69.3%. The major toxicities were similar with the western population and most of them were less than CTCAE grade 3. Most common grade 3 or 4 AEs were anemia, hand-foot syndrome, fatigue, and stomatitis. There were no grade 5 AEs. Conclusions: Our results demonstrate that cabozantinib is an effective treatment option after first line TKI in Korean ccRCC patients with manageable toxicities. Notably, its tolerability in the advanced line of treatment and synergy with ICIs are suggested in this study despite heterogeneous patients of real world setting. This is the first real world data with cabozantinib in Asian patients.

Download Full-text

Real World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Teratiary Care Cancer Center in India

International Journal of Molecular and Immuno Oncology ◽

10.25259/ijmio_1_2019 ◽

2019 ◽

Vol 4 ◽

pp. 63-66

Author(s):

Vineet Talwar ◽

Sneha Jatan Bothra ◽

Varun Goel ◽

Prasanta Kumar Dash ◽

Ankush Jajodia ◽

...

Keyword(s):

Real World ◽

Immune Checkpoint ◽

Renal Cell ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Common Adverse Effect ◽

Cancer Center ◽

Real World Data ◽

World Data ◽

Metastatic Rcc

AIMS: The real-world data regarding the response rates, tolerability, and toxicities of immunotherapy is very limited. The aim of this study is to analyze these characteristics in patients who have received immunotherapy for metastatic renal cell carcinoma (RCC) or urothelial cancer (UC). Methods: Retrospective review of patients over a year from 2017–2018 diagnosed with metastatic RCC and UC in our institute who received checkpoint inhibitors was done. PFS and OS were calculated. Results: A total of 16 patients, 11 with metastatic RCC and 5 patients with Metastatic UC were included in this study. All patients were male and Median age was 57.5 years. Median Number of cycles administered was 6. 50% of patients had a partial response to treatment, 16.6% of patients had stable disease and 33.3% of patients had progressive disease. There were no complete responses to therapy. Median Follow up was 9 months. The median PFS of the whole cohort was 6 months, while in RCC was 6 months and in UC was 1 month. Median OS of the whole cohort is 7 months, while the median OS for RCC and UC were 7 months and 3 months respectively. Fatigue was the most common adverse effect noted and Anaemia was the most common hematological side effect seen with immunotherapy in this study. Conclusion: This is real-world data of the use of the immune checkpoint inhibitors in the resource-limited setting. The benefit of Immune checkpoint inhibitors may in advanced renal cell cancers and Urothelial cancers may be different from that seen in the Western population.

Download Full-text

509P A different epidemiological trend in Brazilian early-onset colorectal cancer (EOCRC): Real-world data from a reference cancer center

Annals of Oncology ◽

10.1016/j.annonc.2020.08.619 ◽

2020 ◽

Vol 31 ◽

pp. S456

Author(s):

A.I.M. Kazzi ◽

T.D.M. Passarini ◽

F.A. Duarte ◽

F.R. Paes ◽

B.L. Ferrari ◽

...

Keyword(s):

Colorectal Cancer ◽

Real World ◽

Early Onset ◽

Cancer Center ◽

Real World Data ◽

World Data ◽

Epidemiological Trend ◽

Early Onset Colorectal Cancer

Download Full-text

A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e16733 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e16733-e16733

Author(s):

Kenneth H. Yu ◽

Andrew Eugene Hendifar ◽

Olatunji B. Alese ◽

Amber Draper ◽

Maen Abdelrahim ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Real World ◽

Chart Review ◽

Medical Center ◽

Ductal Adenocarcinoma ◽

Cancer Center ◽

Real World Data ◽

World Data ◽

Review Study ◽

Liposomal Irinotecan

e16733 Background: Real-world data allows healthcare decision-makers to assess and manage therapeutic and economic options for patients, including those who would and would not have met eligibility criteria for randomized control trials (RCT) and are instead managed under usual care. This retrospective multi-academic center chart review study describes real-world characteristics and outcomes of US patients receiving liposomal irinotecan for the management of metastatic pancreatic ductal adenocarcinoma (mPDAC). Methods: Patients with mPDAC treated with liposomal irinotecan were eligible. Initiation of liposomal irinotecan defined index date; covariates assessed included clinical characteristics and treatment patterns; real-world overall survival (rwOS) was assessed via Kaplan-Meier methodology. The target enrollment is 300 patients. The study centers included were Memorial Sloan Kettering Cancer Center, Cedars-Sinai Medical Center, Emory Winship Cancer Institute, Houston Methodist Cancer Center, Henry Ford Cancer Institute, and University of Pittsburgh Medical Center. Results: Data on 26 patients were available for initial analyses. Mean age was 68 years; 58% were female and 65% Caucasian. 54% of patients had stage IV disease at first diagnosis, and 17%, 65%, and 17% had index ECOG score of 0, 1, and 2, respectively. Common genetic mutations include KRAS (40%) and TP53 (40%). Prior to liposomal irinotecan, treatments received for metastatic disease include gemcitabine+nab-paclitaxel (77%) and fluorouracil (5-FU)/leucovorin (LV)+irinotecan+oxaliplatin (19%). Patients had received 0 (12%), 1 (23%), and ≥2 (65%) lines of therapy in the metastatic setting prior to liposomal irinotecan. Mean duration of liposomal irinotecan use was 3.0 months; liposomal irinotecan was mostly received with 5-FU (23%) or 5-FU/LV (69%). Median rwOS was 4.9 months (95% CI: 3.0, 6.3). Conclusions: Real-world data of the first 26 patients in this study show patients treated with liposomal irinotecan are older, sicker, and have had more lines of therapy than previously reported in RCT data.

Download Full-text

Does order matter? Real-world data on outcomes of successive regimens involving anti-PDx-1 in advanced and metastatic non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e21159 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e21159-e21159

Author(s):

David Hadley ◽

Shady Gendy

Keyword(s):

Real World ◽

Proportional Hazards ◽

The United States ◽

Driver Mutations ◽

Cancer Center ◽

Real World Data ◽

Treatment Protocols ◽

World Data ◽

Nsclc Patients ◽

Platinum Doublet

e21159 Background: In 2020, 65% of newly diagnosed advanced (adv)or metastatic (met) NSCLC patients in US started first line (1L) systemic therapy on anti-PDx-1 regimen, 53% of second line (2L). Between broader approvals of anti-PDx-1, increasing use in different therapy lines, and in different regimen combinations, selecting initial and subsequent regimens can be challenging, especially with limited research on outcomes based on order. This analysis uses real-world data to summarize treatment decisions made in a network of oncology centers and relates them to time to second disease progression (PFS2) and overall survival (OS). PRA US medical & prescription claims – 2020 (Jan-Aug). Methods: Deidentified data on adv/met NSCLC patients were selected from Inteliquet’s Cancer Center Research Consortium partners, which comprises academic & community oncology practices as well as integrated delivery networks across the United States. Analysis was limited to patients who started 1L systemic treatment in 2017 & 2018 (index event), progressed and started 2L. Either 1L / 2L / both must have been anti-PDx-1 based regimen. Patients with known actionable driver mutations were excluded. Data from the following 24 months was used to identify regimens and time to progression. PFS2 and OS across the combined 1L and 2L treatment protocols were assessed by proportional hazards regression. The analysis was adjusted for age at diagnosis, gender, PS and treating organization. Results: 132 patients met the study criteria: 53% were female, the median age range at diagnosis was 60-69 years, and 73% were diagnosed with stage IV, and 76% had PS 0-2 at diagnosis. After 24 months, 86% were alive, all had one progression and 44% had a 2nd progression. The most frequently observed treatment patterns are summarized in the table. Conclusions: Same regimens in different order showed different outcomes. There is a significant benefit for both OS & PFS2 by starting with a platinum doublet followed by IO PT, versus the same start followed by IO MT. There is a significant disadvantage in OS by starting with IO MT followed by platinum doublet, versus the reversed order. 1L IO PT versus baseline showed non-significant improvement in PFS2, but not OS.[Table: see text]

Download Full-text